4.3 Article

Characterization of CD34+hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms

Journal

LEUKEMIA RESEARCH
Volume 48, Issue -, Pages 11-15

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2016.06.009

Keywords

Myeloproliferative neoplasms; JAK2V617F; CALR; Allele burden; Hematopoietic stem cells

Funding

  1. Ministry of Health of Spain
  2. Instituto de Salud Carlos III FEDER [FIS PI10/018087, PI13/00557, PI13/00393, RD12/0036/0010]

Ask authors/readers for more resources

Mutations in JAK2 or CALR are observed in patients with myeloproliferative neoplasms (MPN). To get further insight in the dynamics of the mutant clone, we assessed the mutant allele burden in hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs) and granulocytes from 138 patients [51 polycythemia vera (PV), 58 essential thrombocythemia (ET) and 29 myelofibrosis (MF)]. CALR-mutated ET patients harbored a higher mutant load at progenitor level than JAK2V617F-positive ET (HSCs: 39.9% vs 7.5% p <0.001, HPCs: 32.7% vs 7.7% p <0.001). Moreover, HSCs of CALR-mutated ET patients showed a similar mutational load than patients with CALR-mutated MF (39.9% vs 48.2%, p = 0.17). Regarding JAK2V617F MPN, PV and ET patients showed a low mutational burden at progenitor level whereas in the myelofibrotic phase the dominance of the mutated clone was a constant finding. In conclusion, the size of the mutated clone in chronic phase MPN is different according to genotype with CALR-mutated ET showing a pattern similar to that observed in MF. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available